secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001619856-26-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences FY2025 net loss $148.1M; cash $142.8M funds into 2H 2027
----------------------------------------------------------------------------

- GAAP net loss FY2025 $148.1M ($1.59/sh) vs $149.1M ($1.65) prior year; non-GAAP loss $126.8M excluding $21.3M impairment.
- Revenue FY2025 $11.2M (vs $10.0M in 2024); R&D expenses down to $109.4M due to workforce reduction and pipeline prioritization.
- Cash, equivalents, marketable securities $142.8M at Dec 31, 2025, down from $249.4M; funding expected into 2H 2027; exploring options for pivotal trial.
- Vispa-cel (CB-010) phase 1 data shows efficacy on par with autologous CAR-T; FDA engagement for pivotal trial design; longer follow-up expected 2026.
- CB-011 dose expansion initiated for multiple myeloma; initial data expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/0001619856-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/crbu-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001619856-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer